Search Results - toxin

11 Results

Sort By:

Expression, Purification, and Validation of Anthrax Toxin Proteins

Expression, purification, and validation of anthrax toxin proteins.

Published: 7/25/2024 | Inventor(s): Rasem Fattah, Stephen Leppla

Keywords(s): Anthrax, Expression, proteins, purification, RM, toxin, Validation, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Shihui Liu

Keywords(s): Against, Anthrax, CMG2, EFFICACY, FELINE, FELINE Leukemia, Having, IC2-PA, Improved, Leppla, MARKER, SOLID, Specificity, Strong, Targeting, toxin, tumor, Types, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration

Improved Botulism, Botulinum Neurotoxin Type-E Diagnostics

CDC researchers have improved upon a prior, HHS patented mass spectrometry-based Endopep-MS assay that is able to rapidly detect and differentiate all seven botulinum neurotoxin (BoNT) types A to G. This current improvement comprises the addition of two optimized substrate peptides that increases the assay's sensitivity,relative to prior substrates,...

Published: 7/25/2024 | Inventor(s): Suzanne Kalb, John Barr, Dongxia Wang

Keywords(s): AAXXXX, ACXXXX, BACTERIA, Bacterial, Biodefense, Biodetection, Bolulinum, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DXXXXX, e, MASS SPECTROMETER, Mass spectrometry, Neurotoxin, Novel, Peptide, Recognizable, SUBSTRATES, toxin, TYPE, VBXXXX, VJXXXX, VKXXXX, VLXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, XDXXXX, XHXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines, Application > Consumer Products, Application > Non-Medical Devices, Application > Medical Devices, ResearchProducts > Research Equipment, Application > Research Materials, Application > Diagnostics, Application > Occupational Safety and Health

Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics

CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax...

Published: 7/25/2024 | Inventor(s): Dennis Bagarozzi, Anne Boyer, Conrad Quinn, Jason Goldstein

Keywords(s): Activiating, Activity, Anthracis, Anthrax, AnthraxToxins, Bacillus, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DB3XXX, DB5XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX, Epitope, factor, INFECTIOUS, Lethal, MONITOR, MONITORING, Neutralize, Neutralizing, Region, REGULATING, SCREEN, screening, SERODIAGNOSIS, SERODIAGNOSTIC, Serologic, SEROLOGICAL, therapeutic, Therapeutic/Diagnostic, THERAPY, toxin, TOXIN-BINDING, Vaccine, VBXXXX, VETERINARY, Via, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo, Zoonotic

Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Occupational Safety and Health, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Therapeutics, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, Application > Research Materials, ResearchProducts > Antibodies, Application > Diagnostics

Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine

Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection...

Published: 7/25/2024 | Inventor(s): Conrad Quinn, Jan Pohl, Pavel Svoboda, Shannon Dalton, Jarad Schiffer, Stephen Soroka, Vera Semenova

Keywords(s): Anthrax, ANTIGEN, Bacillus, biosecurity, Bioterrism, Bio-terrorism, Bioterrorist, BioWarfare, CDC Docket Import, CDC Docket Import CDC Prosecuting, DC1XXX, DC4XXX, DCXXXX, Development, DXXXXX, Epitopes, LINEAR, OID-NCIRD-DBD, PA, Peptide, Protection, Protective, toxin, Vaccine

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Published: 7/25/2024 | Inventor(s): Christopher Bachran, Stephen Leppla

Keywords(s): Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics

Engineered Anthrax Toxin Variants that Target Cancer

This technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Damilola Phillips, Clinton Leysath

Keywords(s): Anthrax, ANTIGEN, CB1BXX, CB1XXX, CBXXXX, COMPLEMENTARY, CXXXXX, ENGINEERED, exclusively, FORM, Octamers, Protective, That, toxin, VARIANTS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath

Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases

Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities

Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Andrei Pomerantsev

Keywords(s): Anthracis, Anthrax, ATCC, Bacillus, Bacterial, BH460, DB3XXX, DBXXXX, DC4XXX, DC6XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, HOST, Improved, production, proteins, toxin, vaccines

Category(s): Collaboration Sought > Collaboration, Application > Vaccines, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Infectious Disease

A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency

NIH inventors, in collaboration with Scott and White Memorial Hospital inventors, have developed new immunotoxins comprising a mutant diphtheria toxin linked to an anti-prostate specific membrane antigen (PSMA) fold-back diabody. The fold-back diabody construct has a shortened linker region between the heavy and light chains of the antibody variable...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): A-dmDT390scfbDb591, Anti-prostratic, APPLICATION, Based, BINDING, CANCER, CB1AXX, CB1BXX, CB1CXX, CB1XXX, CBXXXX, CXXXXX, Diabody, DIPHTHERIA, Diptheria, Fold-back, FORMAT, Immunotoxin, IMMUNOTOXINS, INCREASE, particular, Potentcy, That, toxin

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics

1 2